Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=AND			
L3	(hepatitis adj C) and (E adj 2)	27	L3
L2	(hepatitis adj C) and (envelope adj E2)	2	L2
L1	Worman-howard-J$.in.	0	L1

END OF SEARCH HISTORY

```
transcription factor--endogenous compound--ec
MEDICAL DESCRIPTORS:
*protein protein interaction
hybrid; molecular cloning; nonhuman; priority journal; *review*; yeast
SECTION HEADINGS:
  004  Microbiology: Bacteriology, Mycology, Parasitology and Virology
  022  Human Genetics
  029  Clinical and Experimental Biochemistry
?ds

Set     Items   Description
S1         28   (HEPATITIS (W) C) AND (E (W) 2)
S2         11   S1 AND (TREATMENT OR THERAPY OR INHIBITION)
S3          7   RD (unique items)
S4          0   S1 AND REVIEW
S5         17   S1 NOT S2
S6         12   RD (unique items)
S7      24383   (HEPATITIS (W) C) AND (TREATMENT OR THERAPY)
S8       1953   S7 AND REVIEW
S9          0   S8 AND (ENVELOPE (W) E (W) 2)
S10         3   (ENVELOPE (W) E (W) 2) AND (INHIBITION OR PREVENTING)
S11         1   RD (unique items)
S12        76   (YEAST (W) TWO (W) HYBRID) AND (REVIEW)
S13         1   S12 AND (CONFIRMATION OR (FALSE (W) POSITIVE))
?logoff
       28may02 11:49:53 User259876 Session D348.2
            $5.95    1.859 DialUnits File155
               $0.21  1 Type(s) in Format  2
               $1.47  7 Type(s) in Format  3
            $1.68  8 Types
     $7.63  Estimated cost File155
            $7.54    1.346 DialUnits File5
              $19.25  11 Type(s) in Format  3
           $19.25  11 Types
    $26.79  Estimated cost File5
           $16.54    1.838 DialUnits File73
               $2.50  1 Type(s) in Format  2
               $2.50  1 Type(s) in Format  3
            $5.00  2 Types
    $21.54  Estimated cost File73
            OneSearch, 3 files,  5.043 DialUnits FileOS
     $2.81  TELNET
    $58.77  Estimated cost this search
    $59.14  Estimated total session cost   5.135 DialUnits


### Status: Signed Off. (13 minutes)
```

```
### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Welcome to DIALOG
### Status: Connected


Dialog level 02.05.06D

Last logoff:  24may02 10:16:41
Logon file001 28may02 11:37:07
           *** ANNOUNCEMENT ***
                    ***
--Connect Time joins DialUnits as pricing
options on Dialog.  See HELP CONNECT for
information.
                    ***
--SourceOne patents are now delivered to your
email inbox as PDF replacing TIFF delivery.
See HELP SOURCE1 for more information.
                    ***
--Important news for public and academic
libraries.  See HELP LIBRARY for more information.
                    ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
For information about the access to file 43 please see Help News43.
***
NEW FILES RELEASED
***AGROProjects (File 235)
***TRADEMARKSCAN-Japan (File 669)
                    ***
UPDATING RESUMED
***Delphes European Business (File 481)
                    ***
RELOADED
***CLAIMS/US PATENTS (Files 340, 341, 942)
***Kompass Western Europe (590)
***D&B - Dun's Market Identifiers  (516)

REMOVED
***Baton Rouge Advocate (File 382)
***Washington Post (File 146)
***Books in Print (File 470)
***Court Filings (File 793)
***Microcomputer Software Guide Online (File 278)
***Publishers, Distributors & Wholesalers of the U.S. (File 450)
***State Tax Today (File 791)
***Tax Notes Today (File 790)
***Worldwide Tax Daily (File 792)

***New document supplier***
IMED has been changed to INFOTRIE (see HELP OINFOTRI)
```

```
>>>Get immediate news wi[redacted]Dialog's First Release
   news service.  First Release updates major newswire
   databases within 15 minutes of transmission over the
   wire.  First Release provides full Dialog searchability
   and full-text features.  To search First Release files in
   OneSearch simply BEGIN FIRST for coverage from Dialog's
   broad spectrum of news wires.

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                    ****
KWIC is set to 50.
HILIGHT set on as '*'

File   1:ERIC  1966-2002/May 10
       (c) format only 2002 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?b 155, 5, 73
       28may02 11:37:22 User259876 Session D348.1
            $0.32    0.093 DialUnits File1
     $0.32  Estimated cost File1
     $0.05  TELNET
     $0.37  Estimated cost this search
     $0.37  Estimated total session cost   0.093 DialUnits


SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R)  1966-2002/May W3
*File 155: This file has been reloaded. Accession numbers have changed.
  File   5:Biosis Previews(R)  1969-2002/May W3
         (c) 2002 BIOSIS
  File  73:EMBASE  1974-2002/May W3
         (c) 2002 Elsevier Science B.V.
*File  73: For information about Explode feature please
see Help News73.

      Set  Items  Description
      ---  -----  -----------
?s (hepatitis (w) C) and (E (w) 2)
Processing
          273496  HEPATITIS
         2465792  C
           67679  HEPATITIS(W)C
         1505611  E
         7298647  2
           34914  E(W)2
      S1      28  (HEPATITIS (W) C) AND (E (W) 2)
?s s1 and (treatment or therapy or inhibition)
              28  S1
         3808989  TREATMENT
         4404457  THERAPY
         1133458  INHIBITION
      S2      11  S1 AND (TREATMENT OR THERAPY OR INHIBITION)
?rd
...completed examining records
      S3       7  RD (unique items)
?t s3/3,k/all

 3/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12580000   21488940   PMID: 11601926
  Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene
```

including the PePHD and sensitivity of *hepatitis* *C* virus 1b isolates to antiviral *therapy*.

Sarrazin C; Bruckner M; Herrmann E; Ruster B; Bruch K; Roth W K; Zeuzem S
Medizinische Klinik II, J.W. Goethe-Universitat, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

Virology (United States) Oct 10 2001, 289 (1) p150-63, ISSN 0042-6822 Journal Code: 0110674
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of *hepatitis* *C* virus 1b isolates to antiviral *therapy*.

Two regions within the HCV genome, hypervariable region 1 (HVR1) within the envelope (*E*)*2* region and the PKR-binding domain (PKRbD) comprising the interferon sensitivity determining region (ISDR) within the nonstructural (NS)5A protein, have been reported to correlate with the outcome of antiviral *treatment*. Recently, a PKR/eIF2alpha phosphorylation homology domain (PePHD) within the E2 protein of HCV-1 isolates was described to inhibit PKR in vitro. PePHD deleted HCV-1 mutants remain capable of binding PKR to some extent while *inhibition* of PKR was found to be abolished by carboxy-terminal truncated E2 protein. The importance of mutations and quasispecies heterogeneity within the carboxy-terminal part ...

... the PePHD was analyzed by sequencing of PCR products and individual clones of 41 HCV-1b-infected patients with sustained (SR, n = 12), end-of-*treatment* (ETR, n = 10), or no virological (NR, n = 19) response to antiviral *therapy* . Two highly conserved regions (codons 658-673 comprising the PePHD and codons 675-704) and one variable region (codons 705-720) were detected within the carboxy-terminal part of E2. No significant correlation of specific mutations or number of mutations with *treatment* response was observed for the PePHD and the carboxy-terminal part of the E2 protein. Phylogenetic and conformational analyses showed no specific clusters related to *treatment* outcome. Calculation of genetic complexity and diversity based on nucleotide sequence analyses of 20 individual clones per patient showed no differences between matched SR, ETR ...
... and NR patients (P = 0.029 and P = 0.027, respectively). This indicates that patients achieving a sustained virological response to interferon-alpha-based antiviral *therapy* may elicit more effective immunological pressure, resulting in continuous clearing of individual variants of HCV quasispecies. Copyright 2001 Academic Press.

Descriptors: Antiviral Agents--therapeutic use--TU; *Hepacivirus --classification--CL; *Hepacivirus--genetics--GE; **Hepatitis* *C* , Chronic--drug *therapy*--DT; *Interferon-alpha--therapeutic use--TU; *Variation (Genetics); *Viral Envelope Proteins--genetics--GE; Adult; Aged; Amino Acid Sequence; DNA-Binding Proteins--chemistry--CH; DNA-Binding Proteins--genetics--GE; Genes, Viral; Hepacivirus--drug effects--DE; *Hepatitis* *C*, Chronic--virology--VI; Middle Age; Molecular Sequence Data ; Mutation; Phylogeny; Protein Conformation; RNA, Viral--blood--BL; Transcription Factors--chemistry--CH; Transcription Factors--genetics--GE; *Treatment* Outcome; Viral Envelope Proteins--chemistry--CH; Viral Nonstructural Proteins--chemistry--CH; Viral Nonstructural Proteins --genetics--GE; eIF-2 Kinase--chemistry--CH; eIF-2 Kinase--genetics...
Chemical Name: Antiviral Agents; DNA-Binding Proteins; Elf-2 protein; Interferon-alpha; NS-5 protein, *hepatitis* *C* virus; RNA, Viral; Transcription Factors; Viral Envelope Proteins; Viral Nonstructural Proteins; eIF-2 Kinase

3/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09747309 98184843 PM 9516436

***Inhibition* of the *hepatitis* *C* virus helicase-associated ATPase activity by the combination of ADP, NaF, MgCl2, and poly(rU). Two ADP binding sites on the enzyme-nucleic acid complex.**

Porter D J
Glaxo Wellcome, Research Triangle Park, North Carolina 27709, USA.

Journal of biological chemistry (UNITED STATES) Mar 27 1998, 273 (13) p7390-6, ISSN 0021-9258 Journal Code: 2985121R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

***Inhibition* of the *hepatitis* *C* virus helicase-associated ATPase activity by the combination of ADP, NaF, MgCl2, and poly(rU). Two ADP binding sites on the enzyme-nucleic acid complex.**

Hepatitis *C* virus (HCV) helicase has an intrinsic ATPase activity and a nucleic acid (poly(rU))-stimulated ATPase activity. The poly(rU)-stimulated ATPase activity was inhibited by F- in a time-dependent manner during ATP hydrolysis. *Inhibition* was the result of trapping an enzyme-bound ADP-poly(rU) ternary complex generated during the catalytic cycle and was not the result of generating enzyme-free ADP that subsequently inhibited the enzyme. However, catalysis was not required for efficient *inhibition* by F-. The stimulated and the intrinsic ATPase activities were also inhibited by *treatment* of the enzyme with F-, ADP, and poly(rU). The inhibited enzyme slowly recovered (t1/2 = 23 min) ATPase activity after a 2000-fold dilution into assay buffer. The onset of *inhibition* by 500 microM ADP and 15 mM F- in the absence of nucleic acid was very slow (t1/2 > 40 min). However, the sequence of addition of poly(rU) to a diluted solution of ADP/NaF-treated enzyme had a profound effect on the extent of *inhibition*. If the ADP/NaF-treated enzyme was diluted into an assay that lacked poly(rU) and the assay was subsequently initiated with poly(rU), the...

...was not inhibited. Alternatively, if the treated enzyme was diluted into an assay containing poly(rU), the enzyme was inhibited. ATP protected the enzyme from *inhibition* by ADP/NaF. The stoichiometry between ADP and enzyme monomer in the inhibited enzyme complex was 2, as determined from titration of the ATPase activity ([ADP]/[*E*] = *2*.2) and from the number of radiolabeled ADP bound to the inhibited enzyme ([ADP]/[E] = 1.7) in the presence of excess NaF, MgCl2, and...

Chemical Name: Macromolecular Systems; NS3 protein, *hepatitis* *C* virus ; Viral Nonstructural Proteins; Poly U; Adenosine Diphosphate; Deferoxamine ; Aluminum; Beryllium; Sodium Fluoride; Magnesium Chloride; Pyruvate Kinase ; Adenosinetriphosphatase

3/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09691951 98116873 PMID: 9455695

Vitamin E improves the aminotransferase status of patients suffering from viral *hepatitis* *C* : a randomized, double-blind, placebo-controlled study.

von Herbay A; Stahl W; Niederau C; Sies H
Department of Internal Medicine (GI-Unit), Heinrich-Heine-Universitat Dusseldorf, Germany.

Free radical research (SWITZERLAND) Dec 1997, 27 (6) p599-605, ISSN 1071-5762 Journal Code: 9423872
Document type: Clinical Trial; Journal Article; Randomized Controlled Trial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Vitamin E improves the aminotransferase status of patients suffering from

viral *hepatitis* *C* [redacted]a randomized, double-blind, p[redacted]cebo-controlled study.

... by oxidative stress in animal experiments. Based on our previous findings of diminished vitamin E levels in patients suffering from viral hepatitis, we treated 23 *hepatitis* *C* patients refractory to alpha-interferon *therapy* with high doses of vitamin *E* (*2* x 400 IU RRR-alpha-tocopherol/day) for 12 weeks. Study design: pro-spective randomized double-blind crossover design. Clinical parameters including alanine aminotransferase (ALT...

... fold in all 23 patients. In 11 of 23 patients the clinical parameters indicative of liver damage were improved during the phase of vitamin E *treatment* (48% responders). ALT levels in responders were lowered by 46% and AST levels were lowered by 35% after 12 weeks of vitamin E *treatment*. Cessation of vitamin E *treatment* was followed by a rapid relapse of ALT and AST elevation, whereas retreatment led to a reproducible ALT decrease by 45% and AST decrease of 37% after a 6 months followup. Since vitamin E is non-toxic even at elevated doses ingested over extended periods, we suggest the *treatment* of patients refractory to alpha-interferon *therapy* suffering from *hepatitis* *C* with vitamin E as a supportive *therapy*.

Descriptors: Alanine Transaminase--blood--BL; *Antioxidants--pharmacology --PD; *Aspartate Aminotransferases--blood--BL; **Hepatitis* *C*--drug *therapy*--DT; *Vitamin E--pharmacology--PD; Double-Blind Method; *Hepatitis* *C*--enzymology--EN; Middle Age; Placebos

3/3,K/4 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13512110 BIOSIS NO.: 200200140931
Correlation of mutations within the CD81-binding sites and hypervariable region 2 (HVR2) of envelope (*E*)*2* protein with *treatment* response in HCV infected patients.
AUTHOR: Hofmann W Peter(a); Sarrazin Christoph(a); Schoenberger Barbara(a); Bruch Katharina(a); Zeuzem Stefan(a)
AUTHOR ADDRESS: (a)J W Geothe-Universitaet Frankfurt, Frankfurt am Main** Germany
JOURNAL: Hepatology 34 (4 Pt. 2):p425A October, 2001
MEDIUM: print
CONFERENCE/MEETING: 52nd Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases Dallas, Texas, USA November 09-13, 2001
ISSN: 0270-9139
RECORD TYPE: Citation
LANGUAGE: English

Correlation of mutations within the CD81-binding sites and hypervariable region 2 (HVR2) of envelope (*E*)*2* protein with *treatment* response in HCV infected patients.
DESCRIPTORS:
ORGANISMS: *hepatitis* *C* virus (Flaviviridae...
DISEASES: *hepatitis* *C* virus infection...
GENE NAME: *hepatitis* *C* virus E2 gene (Flaviviridae...
ALTERNATE INDEXING: *Hepatitis* *C* (MeSH)

3/3,K/5 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12801442 BIOSIS NO.: 200100008591
Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon *therapy*.
AUTHOR: Chayama Kazuaki(a); Suzuki Fumitaka; Tsubota Akihito; Kobayashi

Masahiro; Arase Yasuji; [redacted]aitoh Satoshi; Suzuki Yoshiyuki; [redacted]urashima Naoya ; Ikeda Kenji; Takahashi Norihiko; Kinoshita Moritoshi; Kumada Hiromitsu
AUTHOR ADDRESS: (a)First Department of Internal Medicine, Hiroshima University School of Medicine, 1-2-3, Kasumi, Minamiku, Hiroshima, 734-8551: chayama@mba.sphere.ne.jp**Japan
JOURNAL: Hepatology 32 (5):p1138-1144 November, 2000
MEDIUM: print
ISSN: 0270-9139
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon *therapy*.

ABSTRACT: *Hepatitis* *C* virus (HCV) genotype 1b and high pretreatment virus load are well known predictive factors of poor response to interferon (IFN) *therapy*. In addition, a sparsity of amino acid substitutions in the interferon sensitivity determining region (ISDR) is also predictive of a poor response IFN in patients...

...domain in the E2 protein of HCV (PKR-eIF2 alpha phosphorylation homology domain (PePHD)) has been reported to bind with and block the virus replication *inhibition* ability of PKR, suggesting that the interaction of E2 and PKR may be one mechanism by which HCV circumvents the antiviral effect to IFN. To clarify the significance of amino-acid sequences in this domain in predicting the effect of IFN *therapy*, we analyzed 82 patients with genotype 1b. Eleven patients (13.4%) responded to *treatment* whereas the remaining 71 patients (86.6%) were nonresponders. Multivariate analysis showed that only HCV load and amino-acid substitutions in the ISDR were predictive...

...8%), and did not correlate with the therapeutic effect of IFN. However, amino-acid-sequence analyses of quasispecies before and after 1 week of IFN *therapy* showed elimination of clones with substitutions in this domain. Our results suggest that amino-acid sequences of the PePHD domain may be related to viral resistance to IFN but do not predict the outcome of IFN *therapy* as amino-acid substitutions in this domain are rare.
DESCRIPTORS:
ORGANISMS: *hepatitis* *C* virus (Flaviviridae...
DISEASES: *hepatitis* *C*--...

...digestive system disease, drug *treatment* response prediction, viral disease
CHEMICALS & BIOCHEMICALS: *hepatitis* *C* virus *E*-*2* protein...

...PKR-eIF-2 phosphorylation homology domain, amino acid sequence, interferon *therapy* response predictor...

...antiviral-drug, gastrointestinal-drug, *treatment* response prediction
ALTERNATE INDEXING: *Hepatitis* *C* (MeSH)

3/3,K/6 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09071439 BIOSIS NO.: 199497079809
Interferon-alpha increases prostaglandin *E*-*2* production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?
AUTHOR: Andreone Pietro(a); Cursaro Carmela; Gasbarrini Giovanni
AUTHOR ADDRESS: (a)I Patol. Med., Univ. Bologna, Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna**Italy
JOURNAL: Journal of Hepatology 19 (2):p228-231 1993

ISSN: 0168-8278
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Interferon-alpha increases prostaglandin *E*-*2* production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?

...ABSTRACT: seem to play an important role in modulating the post-receptorial activity of interferon-alpha. In this study the effect of interferon-alpha on prostaglandin *E*-*2* production was evaluated in cultured liver tissue in 18 patients with chronic active hepatitis related to viral infection (9 hepatitis B virus (HBV) and 9 *hepatitis* *C* virus (HCV) positive) and in 7 uninfected patients with various liver diseases. The results show that interferon-alpha induces a significant increase in prostaglandin *E*-*2* production in both HBV and HCV chronic active hepatitis. Since the *inhibition* of the cyclooxygenase pathway increases antiviral protein synthesis and prostaglandin *E*-*2* has an immunosuppressive activity, this finding seems to suggest that a combined *therapy* (interferon-alpha plus non-steroidal anti-inflammatory drugs) should be indicated at least for patients who do not respond to interferon *therapy* alone.
DESCRIPTORS:
...ORGANISMS: *hepatitis* *C* virus (Flaviviridae

3/3,K/7 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

07243231 EMBASE No: 1998110010
***Inhibition* of the *hepatitis* *C* virus helicase-associated ATPase activity by the combination of ADP, NAF, MgClinf 2, and poly(rU). Two ADP binding sites on the enzyme-nucleic acid complex**
Porters D.J.T.
D.J.T. Porters, Glaxo Wellcome, 5 Moore Dr., Research Triangle Park, NC 27709 United States
Journal of Biological Chemistry (J. BIOL. CHEM.) (United States) 27 MAR 1998, 273/13 (7390-7396)
CODEN: JBCHA ISSN: 0021-9258
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 28

***Inhibition* of the *hepatitis* *C* virus helicase-associated ATPase activity by the combination of ADP, NAF, MgClinf 2, and poly(rU). Two ADP binding sites on the enzyme-nucleic acid...**

Hepatitis *C* virus (HCV) helicase has an intrinsic ATPase activity and a nucleic acid (poly(rU))-stimulated ATPase activity. The poly(rU)-stimulated ATPase activity was inhibited by F- in a time-dependent manner during ATP hydrolysis. *Inhibition* was the result of trapping an enzyme-bound ADP- poly(rU) ternary complex generated during the catalytic cycle and was not the result of generating enzyme-free ADP that subsequently inhibited the enzyme. However, catalysis was not required for efficient *inhibition* by Fsup -. The stimulated and the intrinsic ATPase activities were also inhibited by *treatment* of the enzyme with Fsup -, ADP, and poly(rU). The inhibited enzyme slowly recovered (tinf 1/inf 2 = 23 min) ATPase activity after a 2000-fold dilution into assay buffer. The onset of *inhibition* by 500 muM ADP and 15 mM Fsup - in the absence of nucleic acid was very slow (tinf 1/inf 2 > 40 min). However, the sequence of addition of poly(rU) to a diluted solution of ADP/NaF-treated enzyme had a profound effect on the extent of *inhibition*. If the ADP/NaFtreated enzyme was diluted into an assay that lacked poly(rU) and the assay was subsequently initiated with poly(rU), the treated...

...was not inhibited. Alternatively, if the treated enzyme was diluted into an assay containing poly(rU), the enzyme was inhibited. ATP protected the enzyme from *inhibition* by ADP/NaF. The stoichiometry between ADP and enzyme monomer in the inhibited enzyme complex was 2, as determined from titration of the ATPase activity ((ADP)/(*E*) = *2*.2) and from the number of radiolabeled ADP bound to the inhibited enzyme ((ADP)/(E) = 1.7) in the presence of excess NaF, MgClinf 2...
MEDICAL DESCRIPTORS:
**hepatitis* *c* virus; *enzyme *inhibition*
?ds

```
Set     Items   Description
S1         28   (HEPATITIS (W) C) AND (E (W) 2)
S2         11   S1 AND (TREATMENT OR THERAPY OR INHIBITION)
S3          7   RD (unique items)
?s s1 and review
              28  S1
         1241925  REVIEW
      S4       0  S1 AND REVIEW
?s s1 not s2
              28  S1
              11  S2
      S5      17  S1 NOT S2
?rd
...completed examining records
      S6      12  RD (unique items)
?t s6/3,k/all
```

6/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12601791 21545238 PMID: 11693876
Epidemiology of acute hepatitis in the Stann Creek District of Belize, Central America.
Bryan J P; Reyes L; Hakre S; Gloria R; Kishore G M; Tillett W; Engle R; Tsarev S; Cruess D; Purcell R H
Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799, USA.
American journal of tropical medicine and hygiene (United States) Oct 2001, 65 (4) p318-24, ISSN 0002-9637 Journal Code: 0370507
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... for syphilis. Etiologies of jaundice among 62 evaluable patients included acute hepatitis A, 6 (9.7%), acute hepatitis B, 49 (79.0%), hepatitis non-A-*E*, *2* (3.2%), and malaria, 5 (8.1%). There were no cases of acute hepatitis E. One patient each with antibody to *hepatitis* *C* and D were detected. The annualized incidence of hepatitis A was 0.26 per 1,000. All cases of hepatitis A were in children 4...

6/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11114201 21128831 PMID: 11233845
Acute self-limiting *hepatitis* *C* after possible sexual exposure: sequence analysis of the *E*-*2* region of the infected patient and sexual partner.
Morsica G; Sitia G; Bernardi M T; Tambussi G; Novati R; De Bona A; Gianotti N; Lazzarin A
Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy.
Scandinavian journal of infectious diseases (Sweden) 2001, 33 (2)

p116-20, ISSN 0036-554 Journal Code: 0215333
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Acute self-limiting *hepatitis* *C* after possible sexual exposure: sequence analysis of the *E*-*2* region of the infected patient and sexual partner.

We describe a case of symptomatic acute infection with HCV in a woman whose sexual partner had chronic *hepatitis* *C*. The patient cleared HCV RNA 8 weeks after the onset of acute hepatitis and was found to be persistently HCV-RNA negative during 90 weeks of follow-up. Part of the *E* -*2* region of HCV was directly sequenced in the patient and her sexual partner. Four local controls with subtype-1a infection and 9 1a isolates obtained...

... 19.4% (range 16.6-21.8%) between the sequences of the patient and those of controls. Comparison of the phylogenetic trees in the partial *E*-*2* region showed that the sequence of the patient was closely related to that of her sexual partner. Our findings suggest that the infection was transmitted to the patient from her sexual partner. The resolution of acute *hepatitis* *C* in this case was probably related to the host rather than to intrinsic characteristics of the HCV genome.

Descriptors: Hepacivirus--genetics--GE; **Hepatitis* *C*--transmission --TM; *Sexually Transmitted Diseases--virology--VI; Acute Disease; Adult; *Hepatitis* *C*--blood--BL; RNA, Viral--analysis--AN; Viremia

6/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10614238 20126436 PMID: 10658074

Postoperative hepatic catabolic stress response in patients with cirrhosis and chronic hepatitis.

Lausten S B; El-Sefi T; Marwan I; Ibrahim T M; Jensen L S; Grofte T; Andreasen F; Vilstrup H; Raouf A A; Helmy A; Jensen S L

Department of Surgery, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark.

World journal of surgery (UNITED STATES) Mar 2000, 24 (3) p365-71, ISSN 0364-2313 Journal Code: 7704052

Document type: Clinical Trial; Journal Article; Randomized Controlled Trial

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... 7 in each group). The increase in the functional hepatic nitrogen clearance (FHNC) was quantified. Changes in glucose, insulin, glucagon, cortisol, epinephrine, norepinephrine, and prostaglandin *E*(*2*) (PGE(2)) were observed. There was no difference in FHNC between LC and OC in any of the patients. Among cirrhotic patients OC caused a...

Descriptors: Cholecystectomy--methods--MT; *Cholelithiasis--surgery--SU; **Hepatitis* *C*, Chronic--complications--CO; *Liver--metabolism--ME; *Liver Cirrhosis--complications--CO; *Stress--metabolism--ME; Cholecystecto my, Laparoscopic; Cholelithiasis--complications--CO; *Hepatitis* *C* , Chronic--metabolism--ME; Liver Cirrhosis--metabolism--ME; Liver Function Tests; Middle Age; Nitrogen--metabolism--ME; Statistics, Nonparametric

6/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06619833 90319712 PMID: 2115202

[Transmission of viruses (from A to E) and prevention]

Transmission des virus (de A a E) et prevention.

Jouanolle H; Brissot P
Clinique des maladies du foie, CHRU Pontchaillou, Rennes.
La Revue du praticien (FRANCE) Jun 21 1990, 40 (18) p1660-6, ISSN 0035-2640 Journal Code: 0404334
Document type: Journal Article ; English Abstract
Languages: FRENCH
Main Citation Owner: NLM
Record type: Completed

Recent advances in epidemiology, virology and molecular biology have made it possible: 1) to isolate and characterize the *hepatitis* *C* and D viruses (and soon the virus of hepatitis *E*); *2*) to develop vaccines against hepatitis A and recombinant vaccines against hepatitis B; and 3) to obtain a better understanding of the modes of transmission of...
Descriptors: Hepatitis A--transmission--TM; *Hepatitis B--transmission --TM; **Hepatitis* *C*--transmission--TM; *Hepatitis D--transmission--TM; *Hepatitis, Viral, Human--transmission--TM; Hepatitis A--prevention and control--PC; Hepatitis B--prevention and control--PC; *Hepatitis* *C* --prevention and control--PC; Hepatitis D--prevention and control--PC; Hepatitis E--prevention and control--PC; Hepatitis E--transmission--TM

6/3,K/5 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12717129 BIOSIS NO.: 200000470631
Deletion of hyper variable region-1 of HCV might provide a way to overcome resistance of the virus to immunologic response.
AUTHOR: Kmieciak D(a); Wierzbicki A(a); Biernacka-Lukanty J(a); Migdalski P (a); Juszczyk J(a); Trzeciak W H(a)
AUTHOR ADDRESS: (a)Department of Biochemistry and Molecular Biology and Department of Infectious Diseases, University of Medical Sciences, Poznan **Poland
JOURNAL: Immunology Letters 73 (2-3):p273 September, 2000
MEDIUM: print
CONFERENCE/MEETING: 24th European Immunology Meeting of the European Federation of Immunological Societies (EFIS) Poznan, Poland September 23-26, 2000
SPONSOR: European Federation of Immunological Societies
ISSN: 0165-2478
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

DESCRIPTORS:
ORGANISMS: *hepatitis* *C* virus (Flaviviridae...
CHEMICALS & BIOCHEMICALS: envelope 2 gene {*E*-*2* gene} (Flaviviridae ...

6/3,K/6 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12417222 BIOSIS NO.: 200000170724
Lower hepatitis G virus infection prevalence compared to hepatitis B and C virus infection prevalences.
AUTHOR: Furusyo Norihiro(a); Hayashi Jun; Ariyama Iwao; Sawayama Yasunori; Etoh Yoshitaka; Kashiwagi Seizaburo
AUTHOR ADDRESS: (a)Department of General Medicine, Kyushu University Hospital, Higashi-ku, Fukuoka, 812-8582**Japan
JOURNAL: Digestive Diseases and Sciences. 45 (1):p188-195 Jan., 2000
ISSN: 0163-2116
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: antibody to HGV (anti-E2) by enzyme-linked immunosorbent assay (ELISA) and HGV RNA by nested polymerase chain reaction (PCR) in 298 residents of a *hepatitis* *C* virus (HCV)-endemic area of Japan and in 225 hemodialysis patients. We then compared these findings with known HCV and hepatitis B virus (HBV) infection...
DESCRIPTORS:
...ORGANISMS: *hepatitis* *C* virus (Flaviviridae
...DISEASES: *hepatitis* *C* virus infection
CHEMICALS & BIOCHEMICALS: anti-*E*-*2* antibodies...
ALTERNATE INDEXING: ... *Hepatitis* *C* (MeSH)

6/3,K/7 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12294456 BIOSIS NO.: 200000052323
Comparison of characteristics between patients with GB virus C/hepatitis G virus (GBV-C/HGV) RNA and those with GBV-C/HGV E2-antibody in patients with hemophilia.
AUTHOR: Toyoda Hidenori(a); Takahashi Isao; Fukuda Yoshihide; Hayakawa Tetsuo; Takamatsu Junki
AUTHOR ADDRESS: (a)Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550 **Japan
JOURNAL: Journal of Medical Virology 60 (1):p34-38 Jan., 2000
ISSN: 0146-6615
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: and both the initial age at the first use and years since the first use of blood products. There were no differences in coinfection with *hepatitis* *C* virus (HCV) and/or human immunodeficiency virus, except that infection with HCV subtype 1a was more prevalent in patients with GBV-C/HGV RNA (P...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: GB virus C-hepatitis G virus *E*-*2* antibody
...

6/3,K/8 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12045329 BIOSIS NO.: 199900325848
Evidence for prostaglandin-producing suppressor cells in HCV-specific T cell responses in HCV healthy carriers.
AUTHOR: Marinho R(a); Pinto R(a); Santos L(a); de Moura M Carmeiro(a)
AUTHOR ADDRESS: (a)Liver Unit, Hospital S. Maria, Centre of Gastroenterology, Medical School, Lisbon**Portugal
JOURNAL: Journal of Hepatology 30 (SUPPL. 1):p157 1999
CONFERENCE/MEETING: 34th Annual Meeting of the European Association for the Study of the Liver Naples, Italy April 8-12, 1999
SPONSOR: European Association for the study of the Liver
ISSN: 0168-8278
RECORD TYPE: Citation
LANGUAGE: English

DESCRIPTORS:
ORGANISMS: *hepatitis* *C* virus (Flaviviridae...
DISEASES: *hepatitis* *C*--

CHEMICALS & BIOCHEMICALS prostaglandin *E*-*2*
ALTERNATE INDEXING: *Hepatitis* *C* (MeSH)

6/3,K/9 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11214485 BIOSIS NO.: 199799835630
Clinical significance of HGV/GBV-C infection and its epidemiology in Ontario, Canada.
AUTHOR: Feinman S V(a); Blajchman M A; Hess G; Kim J P; D'Silva L; Krajden M; Mazuli A; Sockanen R
AUTHOR ADDRESS: (a)Liver Study Unit, Mount Sinai Hosp., Univ. Toronto, Toronto, ON**Canada
JOURNAL: Hepatology 26 (4 PART 2):p466A 1997
CONFERENCE/MEETING: 48th Annual Meeting of the American Association for the Study of Liver Diseases Chicago, Illinois, USA November 7-11, 1997
ISSN: 0270-9139
RECORD TYPE: Citation
LANGUAGE: English

DESCRIPTORS:
ORGANISMS: *hepatitis* *C* virus (Flaviviridae...
MISCELLANEOUS TERMS: ...ANTI-*E*-*2*; ...

...*HEPATITIS* *C* VIRUS-RNA

6/3,K/10 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09634781 BIOSIS NO.: 199598089699
Hepatitic bile duct injuries in chronic *hepatitis* *C*: Histopathologic and immunohistochemical studies.
AUTHOR: Kaji Kyosuke; Nakanuma Yasuni(a); Sasaki Motoko; Unoura Masashi; Kobayashi Ken-Ichi; Nonomura Akitaka; Tsuneyama Koichi; Van De Water July ; Gershwin M Eric
AUTHOR ADDRESS: (a)Second Dep. Pathology, Kanazawa Univ. Sch. Med., Kanazawa 920**Japan
JOURNAL: Modern Pathology 7 (9):p937-945 1994
ISSN: 0893-3952
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Hepatitic bile duct injuries in chronic *hepatitis* *C*: Histopathologic and immunohistochemical studies.

...ABSTRACT: primary biliary cirrhosis. In this study, hepatitis bile duct injuries were evaluated histopathologically and immunohistochemically in 149 needle liver biopsy specimens from patients with chronic *hepatitis* *C* and compared immunohistochemically with primary biliary cirrhosis. Fifty-one of the needle biopsies from patients with chronic *hepatitis* *C* (34.2%) showed hepatitis bile duct injuries which were distributed focally in the liver and showed variable epithelial damages such as cytoplasmic swelling, vacuolation and...

...activated T-cells were occasionally found within the biliary epithelial layer. Histopathologic and serial section studies disclosed that bile duct loss was rare in chronic *hepatitis* *C*. Statistical analysis revealed that advancement of chronic hepatitis and the degree of necroinflammatory processes of the liver, particularly in the portal tracts, were positively correlated...

...bile duct injuries. Immunohistochemical studies demonstrated that, whereas strong ectopic expression of HLA-DR and enhanced expression of HLA-A,B,C and pyruvate dehydrogenase *E*-*2*-complex in biliary epithelial cells were frequently observed in chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis, such unusual expressions were generally absent or mild, even if present, in bile duct injuries in chronic *hepatitis* *C*. These findings suggest that hepatitis bile duct injuries are found in a third of chronic *hepatitis* *C* patients, that they are not usually followed by loss of the bile duct, and that their immunopathogenesis is different from that of primary biliary cirrhosis.

6/3,K/11 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09505699 BIOSIS NO.: 199497514069
Performance of third-generation confirmatory tests for detection of antibody to *hepatitis* *C* virus.
AUTHOR: Chaudhary R K(a); Jacobsen H
AUTHOR ADDRESS: (a)Lab. Viral Hepatitis, Bureau Microbiol., Lab. Centre Dis. Control, Health Canada, Ottawa, ON**Canada
JOURNAL: Journal of Clinical Microbiology 32 (10):p2606-2608 1994
ISSN: 0095-1137
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Performance of third-generation confirmatory tests for detection of antibody to *hepatitis* *C* virus.

...ABSTRACT: investigated three immunoblot assays (RIBA 3.0 from Chiron, Matrix from Abbott Laboratories, and LiaTek III from Organon Teknika) for the detection of antibody to *hepatitis* *C* virus. RIBA 3.0 and Matrix require reactivity to two antigens and LiaTek III requires reactivity to one for a sample to be positive. We...
...4 antigen in Matrix (20%) and LiaTek III (16%) was poorly reactive, although it performed better in RIBA 3.0 (45%). The NS-5 and *E*-*2*/NS-1 antigens made minor contributions to reactivity. The combinations of the core, NS-3, and NS-4 antigens produced 77% of the RIBA 3...

6/3,K/12 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08103278 BIOSIS NO.: 000042095476
GENOMIC VARIABILITY WITHIN THE *E*-*2*-NS-1 STRUCTURAL REGION OF *HEPATITIS* *C* VIRUS HCV RESULTS IN ANTIGENICALLY DISTINCT VARIANTS
AUTHOR: LESNIEWSKI R; BOARDWAY K; BUKSH S; CASEY J; DESAI S; MUSHAHWAR I
AUTHOR ADDRESS: EXPERIMENTAL BIOL. RESEARCH, ABBOTT LAB., NORTH CHICAGO, ILL. 60042.
JOURNAL: JOINT ANNUAL MEETING OF THE BIOPHYSICAL SOCIETY AND THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, HOUSTON, TEXAS, USA, FEBRUARY 9-13, 1992. BIOPHYS J 61 (2 PART 2). 1992. A209. 1992
CODEN: BIOJA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

GENOMIC VARIABILITY WITHIN THE *E*-*2*-NS-1 STRUCTURAL REGION OF *HEPATITIS* *C* VIRUS HCV RESULTS IN ANTIGENICALLY DISTINCT VARIANTS
?ds

Set Items Description

```
S1          28   (HEPATITIS (W) C) AND (E (W) 2)
S2          11   S1 AND (TREATMENT OR THERAPY OR INHIBITION)
S3           7   RD (unique items)
S4           0   S1 AND REVIEW
S5          17   S1 NOT S2
S6          12   RD (unique items)
?s (hepatitis (w) C) and (treatment or therapy)
Processing
          273496  HEPATITIS
         2465792  C
           67679  HEPATITIS(W)C
         3808989  TREATMENT
         4404457  THERAPY
      S7   24383  (HEPATITIS (W) C) AND (TREATMENT OR THERAPY)
?s s7 and review
           24383  S7
         1241925  REVIEW
      S8    1953  S7 AND REVIEW
?s s8 and (envelope (w) E (w) 2)
            1953  S8
           78513  ENVELOPE
         1505611  E
         7298647  2
              11  ENVELOPE(W)E(W)2
      S9       0  S8 AND (ENVELOPE (W) E (W) 2)
?s (envelope (w) E (w) 2) and (inhibition or preventing)
           78513  ENVELOPE
         1505611  E
         7298647  2
              11  ENVELOPE(W)E(W)2
         1133458  INHIBITION
          119960  PREVENTING
     S10       3  (ENVELOPE (W) E (W) 2) AND (INHIBITION OR PREVENTING)
?rd
...completed examining records
     S11       1  RD (unique items)
?t s11

 11/2/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12580000   21488940   PMID: 11601926
```

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.

Sarrazin C; Bruckner M; Herrmann E; Ruster B; Bruch K; Roth W K; Zeuzem S
Medizinische Klinik II, J.W. Goethe-Universitat, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

Virology (United States) Oct 10 2001, 289 (1) p150-63, ISSN 0042-6822 Journal Code: 0110674
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Tags: Human; Support, Non-U.S. Gov't

Descriptors: *Antiviral Agents--therapeutic use--TU; *Hepacivirus --classification--CL; *Hepacivirus--genetics--GE; *Hepatitis C, Chronic --drug therapy--DT; *Interferon-alpha--therapeutic use--TU; *Variation (Genetics); *Viral Envelope Proteins--genetics--GE; Adult; Aged; Amino Acid Sequence; DNA-Binding Proteins--chemistry--CH; DNA-Binding Proteins --genetics--GE; Genes, Viral; Hepacivirus--drug effects--DE; Hepatitis C, Chronic--virology--VI; Middle Age; Molecular Sequence Data; Mutation; Phylogeny; Protein Conformation; RNA, Viral--blood--BL; Transcription Factors--chemistry--CH; Transcription Factors--genetics--GE; Treatment Outcome; Viral Envelope Proteins--chemistry--CH; Viral Nonstructural

Proteins--chemistry--CH; Viral Nonstructural Proteins--genetics--GE; eIF-2 Kinase--chemistry--CH; eIF-2 Kinase--genetics--GE
Molecular Sequence Databank No.: GENBANK/AJ343961; GENBANK/AJ343962; GENBANK/AJ343963; GENBANK/AJ343964; GENBANK/AJ343965; GENBANK/AJ343966; GENBANK/AJ343967; GENBANK/AJ343968; GENBANK/AJ343969; GENBANK/AJ343970; GENBANK/AJ343971; GENBANK/AJ343972; GENBANK/AJ343973; GENBANK/AJ343974; GENBANK/AJ343975; GENBANK/AJ343976; GENBANK/AJ343977; GENBANK/AJ343978; GENBANK/AJ343979; GENBANK/AJ343980; GENBANK/AJ343981; GENBANK/AJ343982; GENBANK/AJ343983; GENBANK/AJ343984; GENBANK/AJ343985; GENBANK/AJ343986; GENBANK/AJ343987; GENBANK/AJ343988; GENBANK/AJ343989; GENBANK/AJ343990; GENBANK/AJ343991; GENBANK/AJ343992; GENBANK/AJ343993; GENBANK/AJ343994; GENBANK/AJ343995; GENBANK/AJ343996; GENBANK/AJ343997; GENBANK/AJ343998; GENBANK/AJ343999; GENBANK/AJ344000; GENBANK/AJ344001
CAS Registry No.: 0 (Antiviral Agents); 0 (DNA-Binding Proteins); 0 (Elf-2 protein); 0 (Interferon-alpha); 0 (NS-5 protein, hepatitis C virus); 0 (RNA, Viral); 0 (Transcription Factors); 0 (Viral Envelope Proteins); 0 (Viral Nonstructural Proteins)
Enzyme No.: EC 2.7.10.- (eIF-2 Kinase)
Record Date Created: 20011016
?ds

Set	Items	Description
S1	28	(HEPATITIS (W) C) AND (E (W) 2)
S2	11	S1 AND (TREATMENT OR THERAPY OR INHIBITION)
S3	7	RD (unique items)
S4	0	S1 AND REVIEW
S5	17	S1 NOT S2
S6	12	RD (unique items)
S7	24383	(HEPATITIS (W) C) AND (TREATMENT OR THERAPY)
S8	1953	S7 AND REVIEW
S9	0	S8 AND (ENVELOPE (W) E (W) 2)
S10	3	(ENVELOPE (W) E (W) 2) AND (INHIBITION OR PREVENTING)
S11	1	RD (unique items)

?s (yeast (w) two (w) hybrid) and (review)

	228535	YEAST
	4307491	TWO
	153456	HYBRID
	9190	YEAST(W)TWO(W)HYBRID
	1241925	REVIEW
S12	76	(YEAST (W) TWO (W) HYBRID) AND (REVIEW)

?s s12 and (confirmation or (false (w) positive))

	76	S12
	53459	CONFIRMATION
	116728	FALSE
	1319806	POSITIVE
	56224	FALSE(W)POSITIVE
S13	1	S12 AND (CONFIRMATION OR (FALSE (W) POSITIVE))

?t s13

13/2/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

06035575 EMBASE No: 1995065815
The *yeast* *two*-*hybrid* system for studying protein-protein interactions
Luban J.; Goff S.P.
Howard Hughes Medical Institute, Dept. Biochem. Molecular Biophysics, Columbia University, 630 West 168th Street,New York, NY 10032 United States
Current Opinion in Biotechnology (CURR. OPIN. BIOTECHNOL.) (United Kingdom) 1995, 6/1 (59-64)
CODEN: CUOBE ISSN: 0958-1669
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
DRUG DESCRIPTORS: